3rd Sep 2008 07:00
GENETHERA WITHDRAWS POTENTIAL OFFER FOR OXFORD BIOMEDICA
WHEAT RIDGE, CO, September 2, 2008 - Further to its earlier announcements, GeneThera, Inc, hereby confirms that, at the same time as it continues to evaluate a variety of potential commercial transactions with Oxford Biomedica plc, it has decided not to make an offer for Oxford Biomedica plc.
For the purposes of Rule 2.8 of the City Code on Takeovers and Mergers (the "Code"), GeneThera, Inc. reserves the right to make or participate in an offer or possible offer for Oxford Biomedica plc within six months of the date of this announcement: (1) with the recommendation of the board of Oxford Biomedica plc; (2) upon the announcement of an offer by a third party for Oxford Biomedica plc; (3) upon the announcement by or on behalf of Oxford Biomedica plc of a "whitewash" proposal (as such term is defined in the Code) or of a reverse takeover (as such term is defined in the Code); or (4) if there is a material change of circumstances.
ABOUT GENETHERA, INC.:
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression system, GES, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priority being Mad Cow disease, Chronic Wasting Disease, a disease affecting elk and deer in North America; E. Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide.
GeneThera, Inc.
Dr. Tony Milici, 303-463-6371
http://www.genethera.net
JR Dopkin & Associates
[email protected]; 516-884-3200
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Related Shares:
Oxford Biomedica